Unilife (UNIFF) 10-Q 10 Feb 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Dec. 31, 2013	Feb. 07, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Dec-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'UNIS	'
Entity Registrant Name	'Unilife Corp	'
Entity Central Index Key	'0001476170	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	102,653,512

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$4,314	$5,736
Restricted cash	2,400	2,400
Accounts receivable	2,748	654
Inventories	55	71
Prepaid expenses and other current assets	337	409
Total current assets	9,854	9,270
Property, plant and equipment, net	45,312	46,106
Goodwill	11,166	11,498
Intangible assets, net	21	23
Other assets	652	1,504
Total assets	67,005	68,401
Current Liabilities:	'	'
Accounts payable	1,785	3,428
Accrued expenses	3,577	2,444
Current portion of long-term debt	5,596	3,826
Deferred revenue	'	3,010
Total current liabilities	10,958	12,708
Long-term debt, less current portion	19,560	20,045
Deferred revenue	10,068	50
Total liabilities	40,586	32,803
Contingencies (Note 9)	'	'
Stockholders' Equity:	'	'
Preferred stock, $0.01 par value, 50,000,000 shares authorized as of December 31, 2013; none issued or outstanding as of December 31, 2013 and June 30, 2013	'	'
Common stock, $0.01 par value, 250,000,000 shares authorized as of December 31, 2013; 100,787,182 and 95,602,558 shares issued, and 100,758,512 and 95,573,888 shares outstanding as of December 31, 2013 and June 30, 2013, respectively	1,008	956
Additional paid-in-capital	286,735	268,157
Accumulated deficit	-263,359	-235,832
Accumulated other comprehensive income	2,175	2,457
Treasury stock, at cost, 28,670 shares as of December 31, 2013 and June 30, 2013, respectively	-140	-140
Total stockholders' equity	26,419	35,598
Total liabilities and stockholders' equity	$67,005	$68,401

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	100,787,182	95,602,558
Common stock, shares outstanding	100,758,512	95,573,888
Treasury stock, shares	28,670	28,670

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Statement Of Income And Comprehensive Income [Abstract]	'	'	'	'
Revenue	$3,573	$699	$6,760	$1,391
Cost of product sales	'	22	'	81
Gross profit	3,573	677	6,760	1,310
Operating expenses:	'	'	'	'
Research and development	7,807	4,994	14,206	9,732
Selling, general and administrative	6,703	8,327	13,223	14,904
Depreciation and amortization	1,000	1,365	2,042	2,588
Total operating expenses	15,510	14,686	29,471	27,224
Operating loss	-11,937	-14,009	-22,711	-25,914
Interest expense	4,351	645	4,831	1,261
Interest income	-5	-14	-11	-38
Other income, net	'	'	-4	'
Net loss	-16,283	-14,640	-27,527	-27,137
Other comprehensive (income) loss, net:	'	'	'	'
Foreign currency translation	543	5	282	-168
Comprehensive loss	($16,826)	($14,645)	($27,809)	($26,969)
Net loss per share:	'	'	'	'
Basic and diluted net loss per share	($0.17)	($0.19)	($0.29)	($0.35)

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Treasury Stock [Member]
In Thousands, except Share data
Beginning balance at Jun. 30, 2013	$35,598	$956	$268,157	($235,832)	$2,457	($140)
Beginning balance, shares at Jun. 30, 2013	'	95,602,558	'	'	'	'
Net loss	-27,527	'	'	-27,527	'	'
Foreign currency translation	-282	'	'	'	-282	'
Share-based compensation expense	5,271	4	5,267	'	'	'
Share-based compensation expense, shares	'	348,000	'	'	'	'
Issuance of common stock from public offerings, net of issuance costs	10,668	35	10,633	'	'	'
Issuance of common stock from public offerings, net of issuance costs, shares	3,512,153	3,512,153	'	'	'	'
Issuance of common stock upon exercise of stock options	2,691	13	2,678	'	'	'
Issuance of common stock upon exercise of stock options, shares	'	1,324,471	'	'	'	'
Ending balance at Dec. 31, 2013	$26,419	$1,008	$286,735	($263,359)	$2,175	($140)
Ending balance, shares at Dec. 31, 2013	'	100,787,182	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:	'	'
Net loss	($27,527)	($27,137)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	2,042	2,588
Share-based compensation expense	5,271	4,518
Recognition of deferred revenue	-3,187	-1,276
Non-cash interest expense	3,610	'
Changes in assets and liabilities:	'	'
Accounts receivable	-1,851	938
Inventories	16	56
Prepaid expenses and other current assets	71	-37
Other assets	2	6
Accounts payable	-658	-606
Accrued expenses	1,211	215
Deferred revenue	10,000	'
Net cash used in operating activities	-11,000	-20,735
Cash flows from investing activities:	'	'
Purchases of property, plant and equipment	-1,798	-1,321
Net cash used in investing activities	-1,798	-1,321
Cash flows from financing activities:	'	'
Principal payments on long-term debt and capital lease obligations	-1,661	-2,401
Proceeds from the issuance of common stock and warrants, net of issuance costs	10,668	18,780
Proceeds from the exercise of options to purchase common stock	2,305	171
Net cash provided by financing activities	11,312	16,550
Effect of exchange rate changes on cash	64	10
Net decrease in cash and cash equivalents	-1,422	-5,496
Cash and cash equivalents at beginning of period	5,736	11,410
Cash and cash equivalents at end of period	4,314	5,914
Supplemental disclosure of non-cash activities	'	'
Purchases of property, plant and equipment in accounts payable and accrued expenses	$59	$119

Description_of_Business_and_Un

Description of Business and Unaudited Financial Statements	6 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Description of Business and Unaudited Financial Statements	'
	1. Description of Business and Unaudited Financial Statements
	Unilife Corporation and subsidiaries (the “Company”) is a U.S. based manufacturer and supplier of injectable drug delivery systems. The Company’s customers are biotechnology companies who seek to leverage its innovative, differentiated and customizable devices to enable or enhance the clinical development, regulatory approval and commercial lifecycles of its injectable biologics, drugs and vaccines. The Company manufactures and supplies its proprietary devices to pharmaceutical companies in a format where they can be filled and packaged with an injectable therapy prior to its shipment to the end-user for safe, simple and convenient administration.
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited consolidated financial statements contain all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation for the periods presented as required by Rule 10-01 of Regulation S-X. Interim results may not be indicative of results for a full year. The accompanying unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the fiscal year ended June 30, 2013 contained in its Annual Report on Form 10-K.
	References to A$ mean the lawful currency of the Commonwealth of Australia. References to € or euros are to the lawful currency of the European Union.

Liquidity

Liquidity	6 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Liquidity	'
	2. Liquidity
	The Company has incurred recurring losses from operations during the year ended June 30, 2013, and the six months ended December 31, 2013, and anticipates incurring additional losses until such time that it can generate sufficient revenue from the sale, customization, or exclusive use and licensing of its proprietary range of injectable drug delivery systems to pharmaceutical and biotechnology customers. Management has taken such steps delineated below to address its cash requirements.
	The Company needs additional funding to support its operations and capital expenditure requirements. The Company continues to have discussions with current and prospective customers for many active programs in its commercial pipeline and has executed several agreements featuring a combination of revenue streams including exclusivity fees, device customization programs and supply contracts that have begun to generate cash payments to the Company during fiscal year 2014. The Company expects to continue to execute agreements and generate additional cash payments during the remainder of calendar year 2014. Given the substantial size, complexity and long-term duration of many of these prospective agreements, some can take a significant time to negotiate and finalize. The Company is managing its cash position to minimize raising additional equity capital with the objective of minimizing dilution to existing stockholders.
	The Company continues to evaluate debt funding programs available to the Company as part of its overall financing strategy. Combined with the anticipated revenue to be generated from new and existing customer agreements or through other transactions, the Company expects to have sufficient near term liquidity. However, there can be no assurance that such additional funding, or sales transactions, will close as expected or be available when needed. These various factors continue to raise substantial doubt about the Company’s ability to continue as a going concern.
	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
	In October 2012, the Company entered into a Controlled Equity Offering Sales Agreement, (the “Sales Agreement”) pursuant to which the Company may, from time to time, issue and sell shares of common stock having an aggregate offering price of up to $45.0 million. During the six months ended December 31, 2013, the Company issued 3,512,153 shares of common stock and raised approximately $10.7 million under the Sales Agreement. The Company is not obligated to make any additional sales of shares under the Sales Agreement. As of December 31, 2013, there was approximately $19.2 million available under the Sales Agreement. Subsequent to December 31, 2013, the Company issued 1,500,000 shares of common stock and raised approximately $6.2 million under the Sales Agreement.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	3. Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of Unilife Corporation and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The estimates are principally in the areas of revenue recognition and share-based compensation expense. Management bases its estimates on historical experience and various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.
	Inventories
	Inventories consist primarily of syringe components and include direct materials, direct labor and manufacturing overhead. Inventories are stated at the lower of cost or market, with cost determined using the first in, first out method. The Company routinely reviews its inventory for obsolete, slow moving or otherwise impaired inventory and records estimated impairments in the periods in which they occur.
	Share-Based Compensation
	The Company grants equity awards to its employees, directors and consultants. Certain employee and director awards vest over stated vesting periods and others also require achievement of specific performance or market conditions. The Company expenses the grant-date fair value of awards to employees and directors over their respective vesting periods. To the extent that employee and director awards vest only upon the achievement of a specific performance condition, expense is recognized over the period from the date management determines that the performance condition is probable of achievement through the date they are expected to be met. Awards granted to consultants are sometimes granted for past services, in which case their fair value is expensed on their grant date, while other awards require future service, or the achievement of performance or market conditions. Timing of expense recognition for consultant awards is similar to that of employee and director awards; however, aggregate expense is re-measured each quarter-end based on the then fair value of the award through the vesting date of the award. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model, with the exception of market-based grants, which are valued based on the Monte Carlo option pricing model. Option pricing methods require the input of highly subjective assumptions, including the expected stock price volatility.
	Revenue Recognition
	The Company recognizes revenue from industrialization and development fees, licensing fees and product sales.
	The Company recognizes up front, non-refundable fees ratably over the expected life of the related agreement. Revenue from industrialization and development fees is recognized upon achievement of the “at risk” milestone events, which represent the culmination of the earnings process related to such events. Milestones can include specific phases of projects such as product design, prototype availability, user tests, manufacturing proof of principle and the various steps to complete the industrialization of the product. Revenue is recognized when each substantive milestone has been achieved and the Company has no future performance obligations related to the milestone.
	The Company recognizes revenue from sales of products at the time of shipment when title passes to the customer.
	Reclassifications
	Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.
	Recently Issued Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” (“ASU 2013-02”). The new guidance requires an entity to disclose in a single location the effects of reclassifications out of accumulated other comprehensive income (“AOCI”). For items reclassified out of AOCI and into net income in their entirety, entities must disclose the effect of the reclassification on each affected net income item. For AOCI reclassification items that are not reclassified in their entirety into net income, entities must provide a cross reference to other required U.S. GAAP disclosures. The standard does not change the items which must be reported in other comprehensive income. ASU 2013-02 is effective for annual and interim periods for fiscal years beginning after December 15, 2012. Since this guidance impacts presentation only, it has had no effect on the Company’s financial condition.
	In July 2013, the FASB issued ASC 2013-11, “Income Taxes — Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”) which is part of Accounting Standards Codification (“ASC”) 740: Income Taxes. The new guidance requires an entity to present an unrecognized tax benefit and an NOL carryforward, a similar tax loss, or a tax credit carryforward on a net basis as part of a deferred tax asset, unless the unrecognized tax benefit is not available to reduce the deferred tax asset component or would not be utilized for that purpose, then a liability would be recognized. ASU 2013-11 is effective for annual and interim periods for fiscal years beginning after December 15, 2013. The Company is currently evaluating the impact of the July 1, 2014 adoption of this guidance on its financial statements.

Equity_Transactions_and_ShareB

Equity Transactions and Share-Based Compensation	6 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Equity Transactions and Share-Based Compensation	'
	4. Equity Transactions and Share-Based Compensation
	The Company recognized share-based compensation expense related to equity awards to employees, directors and consultants of $2.6 million and $2.9 million during the three months ended December 31, 2013 and 2012, respectively and $5.3 million and $4.5 million during the six months ended December 31, 2013 and 2012, respectively.
	During the three months ended December 31, 2013 the Company granted certain directors 227,500 shares of common stock which may not be sold or transferred until such time as the director leaves the board for any reason, including a change in control, or other permitted circumstances. The weighted average grant date fair value of the shares was $3.95 per share.
	Stock Options and Warrants
	The Company has granted stock options to certain employees and directors under the Employee Share Option Plan (the “Plan”). The Plan is designed to assist in the motivation and retention of employees and to recognize the importance of employees to the long-term performance and success of the Company. The Company has also granted stock options to certain consultants outside of the Plan. The majority of the options to purchase common stock vest on the anniversary of the date of grant, which ranges from one to three years. Additionally, certain stock options vest upon the closing price of the Company’s common stock reaching certain minimum levels, as defined in the agreements. Share-based compensation expense related to options granted to employees is recognized on a straight-line basis over the related vesting term. Share-based compensation expense related to options granted to consultants is recognized ratably over each vesting tranche of the options.
	In November 2009, the Company adopted the 2009 Stock Incentive Plan (the “Stock Incentive Plan”). The Stock Incentive Plan initially provided for a maximum of 6,000,000 shares of common stock to be reserved for the issuance of stock options and other stock-based awards. Commencing on January 1, 2012, and on each January 1st thereafter, through January 1, 2019, the share reserve automatically adjusts so that it equals 17.5% of the weighted average number of shares of common stock outstanding reduced by the sum of any shares of common stock issued under the Stock Incentive Plan and any shares of common stock subject to outstanding awards under the Stock Incentive Plan.
	In January 2010, the Company issued 1,000,000 options to purchase common stock to a consultant under the Stock Incentive Plan in consideration for various services to be performed for the Company. The options to purchase common stock are exercisable at A$6.33 per share and vest upon the trading price of the Company’s CHESS Depositary Interests reaching certain minimum levels on the Australian Securities Exchange, which range from A$1.75 to A$3.22 per share. The options are re-measured each reporting date and as of December 31, 2013 were valued at $0.97 per option, which is being expensed ratably over the vesting period of each tranche, which ranges from 0.61 years to 0.78 years. The options will be re-valued on a quarterly basis and marked to market until exercised.
	The following is a summary of activity related to stock options held by employees and directors during the six months ended December 31, 2013:
		Number of			Weighted			Weighted		Aggregate Intrinsic
		Options			Average			Average		Value
					Exercise Price			Remaining
								Contractual
								Life (in years)
										(in thousands)
	Outstanding as of July 1, 2013		5,121,807		$	4.05
	Cancelled		(74,396	)		5.55
	Exercised		(1,250,000	)		1.76
	Outstanding as of December 31, 2013		3,797,411		$	4.77			5.5	$	2,068
	Exercisable as of December 31, 2013		1,666,024		$	4.8			5.7	$	755
	The following is a summary of activity related to stock options and warrants held by persons other than employees and directors during the six months ended December 31, 2013:
		Number of			Weighted			Weighted		Aggregate Intrinsic
		Options			Average			Average		Value
					Exercise Price			Remaining
								Contractual
								Life (in years)
										(in thousands)
	Outstanding as of July 1, 2013		4,258,937		$	6.89
	Granted		300,000			3.11
	Exercised		(155,000	)		2.56
	Expired		(2,268,934	)		8.65
	Outstanding as of December 31, 2013		2,135,003		$	4.8			1.9	$	888
	Exercisable as of December 31, 2013		1,135,003		$	4.09			2.6	$	888
	The aggregate intrinsic value is defined as the difference between the market value of the Company’s common stock as of the end of the period and the exercise price of the in-the-money stock options. The total intrinsic value of stock options exercised during the three months ended December 31, 2013 and 2012 was $0 and $0.1 million, respectively. The total intrinsic value of stock options exercised during the six months ended December 31, 2013 and 2012 was $1.8 million and $0.1 million, respectively.
	The Company used the following weighted average assumptions in calculating the fair value of options granted during the six months ended December 31, 2013 and 2012:
		Six Months Ended
		December 31,
		2013			2012
	Number of stock options granted		300,000			300,000
	Expected dividend yield		0	%		0	%
	Risk-free interest rate		1.54	%		0.91	%
	Expected volatility		55	%		55	%
	Expected life (in years)		5			6
	The fair value of each stock option was estimated at the grant date using the Black-Scholes option pricing model, with the exception of grants subject to market conditions, which were valued using a Monte Carlo option pricing model. The Company has not historically paid dividends to its stockholders and, as a result, assumed a dividend yield of 0%. The risk free interest rate is based upon the rates of U.S. Treasury bonds with a term equal to the expected term of the option. Due to the Company’s limited Nasdaq trading history, the expected volatility used to value options granted after January 27, 2010 is based upon a blended rate of the historical share price of the Company’s stock on the Australian Securities Exchange and the volatility of peer companies traded on U.S. exchanges operating in the same industry as the Company. The expected term of the options to purchase common stock issued to employees and directors is based upon the simplified method, which is the mid-point between the vesting date of the option and its contractual term unless a reasonable alternate term is estimated by management. The expected term of the options to purchase common stock issued to consultants is based on the contractual term of the awards.
	Restricted Stock
	The Company has granted shares of restricted stock to certain employees and consultants under the Stock Incentive Plan. During the period prior to vesting, the holder of the non-vested restricted stock will have the right to vote and the right to receive all dividends and other distributions declared. All non-vested shares of restricted stock are reflected as outstanding; however, they have been excluded from the calculation of basic earnings per share.
	For employees, the fair value of restricted stock is measured on the date of grant using the price of the Company’s common stock on that date. Share-based compensation expense for restricted stock issued to employees is recognized on a straight-line basis over the requisite service period, which is generally the longest vesting period. For restricted stock granted to consultants, the fair value of the awards is re-valued on a quarterly basis and marked to market until vested. Share-based compensation expense for restricted stock issued to consultants is recognized ratably over each vesting tranche.
	The following is a summary of activity related to restricted stock awards during the six months ended December 31, 2013:
		Number of Restricted			Weighted Average
		Stock Awards			Grant Date Fair Value
	Unvested as of July 1, 2013		3,254,403		$	3.31
	Granted		75,000			3.54
	Vested		(929,150	)		3.35
	Cancelled		(4,500	)		3.46
	Unvested as of December 31, 2013		2,395,753		$	3.3

Property_Plant_and_Equipment_a

Property, Plant and Equipment and Construction-in-Progress	6 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment and Construction-in-Progress	'
	5. Property, Plant and Equipment and Construction-in-Progress
	Property, plant and equipment consist of the following:
		December 31,			June 30,
		2013			2013
		(in thousands)
	Building	$	32,188		$	32,188
	Machinery and equipment		18,632			21,682
	Computer software		2,653			2,653
	Furniture and fixtures		583			374
	Construction in progress		481			91
	Land		2,036			2,036
	Leasehold improvements		166			88
			56,739			59,112
	Less: accumulated depreciation and amortization		(11,427	)		(13,006	)
	Property, plant and equipment, net	$	45,312		$	46,106

Goodwill

Goodwill	6 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	6. Goodwill
	The changes in the carrying amount of goodwill during the six months ended December 31, 2013 are as follows:
		(in thousands)
	Balance as of July 1, 2013	$	11,498
	Foreign currency translation		(332	)
	Balance as of December 31, 2013	$	11,166

LongTerm_Debt

Long-Term Debt	6 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	7. Long-Term Debt
	Long-term debt consists of the following:
		December 31, 2013		June 30, 2013
		(In thousands)
	6.00% Mortgage loan, due December 2031	$	13,474	$	13,677
	6.00% Mortgage loan, due October 2020		3,170		3,322
	14.00% Secured lending facility, due December 2014		4,364		2,586
	4.75% Bank term loans, due January 2021 through August 2021		1,611		1,701
	5.00% Commonwealth of Pennsylvania financing authority loan, due January 2021		2,108		2,133
	Other		429		452
			25,156		23,871
	Less: current portion of long-term debt		5,596		3,826
	Total long-term debt	$	19,560	$	20,045
	Mortgage Loans
	In October 2010, Unilife Cross Farm LLC, a wholly owned subsidiary of the Company, (“Cross Farm”) entered into a loan agreement with Metro Bank (“Metro”), pursuant to which Metro provided Cross Farm with two mortgage loans in the amounts of $14.25 million and $3.75 million. The proceeds received were used to finance the purchase of land and construction of the Company’s corporate headquarters and manufacturing facility in York, Pennsylvania.
	During construction, Cross Farm paid only interest on both term loans at the Prime Rate plus 1.50% per annum, with a floor of 4.50% per annum. Subsequent to construction, Cross Farm is paying principal and interest on both term loans, with interest at a fixed rate of 6.00%. The weighted average interest rate on both term notes was 6.00% during the six months ended December 31, 2013 and the year ended June 30, 2013.
	The loan agreement contains certain customary covenants, including the maintenance of a Debt Service Reserve Account in the amount of $2.4 million, classified as restricted cash on the consolidated balance sheet, which will remain in place until Cross Farm and Metro agree on the financial covenants. The terms of the loan agreement allow the Company to use the Debt Service Reserve Account to pay monthly debt service on the mortgage loans, so long as the balance in the account is at least $1.6 million and is replenished to $2.4 million every six months. The Company was in compliance with its debt covenants as of December 31, 2013. However, there can be no assurance that the Company will be able to maintain the Debt Service Reserve Account balance for a period of 12 months from December 31, 2013. Cross Farm may prepay the loan without penalty. The U.S. Department of Agriculture has guaranteed $10.0 million of the loans.
	In connection with the two mortgage loans and other bank term loans, the Company has given Metro Bank a lien on substantially all of the Company’s assets except for the Company’s intellectual property and certain other assets that are subject to other third party liens.
	Secured Lending Facility
	In August 2011, the Company entered into a Master Lease Agreement (the “Lease Agreement”) with Varilease Finance, Inc. (“Varilease”) for up to $10.0 million of secured financing for production equipment for its Unifill syringe. Based on the Company’s continuing involvement throughout the term of the agreement and the integral nature of the production equipment, the transaction is being accounted for as a financing. Over the term of the Lease Agreement, the Company made 27 monthly installments based upon the amount drawn. This facility has an effective interest rate of 14.00%. The secured lending facility contains covenants and provisions for events of default customarily found in lease agreements.
	As previously disclosed on September 30, 2013, Varilease and CCA Financial LLC (collectively, the “Lessors”) filed an action in the State of Michigan in the Circuit Court for the County of Oakland, Case No. 2013-136458-CK seeking a judgment confirming the terms of the lease. The Company removed the action to the U.S. District Court for the Eastern District of Michigan, Case No. 2:13-CV-14238-SFC-LJM, on October 4, 2013. Under the Lease Agreement, Lessors and the Company were to negotiate a buyout rate at the end of the two-year lease term, which Lessors represented to the Company during the lease negotiations would be 15% of the amount financed. When the Company notified Lessors that it wanted to exercise the buyout of the equipment, Lessors claimed a buyout rate significantly higher than 15%. Under the terms of the lease, if the parties are unable to agree on a buyout rate by the end of the lease term, the lease will automatically renew for an additional 12-month period and the Company would be responsible for another year of lease payments. Lessor’s action in Michigan state court asked the court to confirm that the parties have been unable to agree on a buyout rate and therefore under the terms of the lease the lease is automatically extended for one year.
	As previously disclosed, the Company also filed suit on September 30, 2013 against Lessors in the U.S. District Court for the Eastern District of Michigan, Case No. 2:13-cv-14174-SFC-LJM alleging, among other things, that Lessors fraudulently induced the Company into entering the lease by making misrepresentations about the buyout rate. The Company sought, among other things, to have the federal court enforce a 15% buyout rate and to enjoin Lessors from declaring a default under the lease and taking possession of the equipment for which the Company would have to impair the carrying value of assets. On October 17, 2013, in a stipulated order, the U.S. District Court ordered that the Company continue to make the same monthly payments under the lease, that as long as the Company makes timely payments, Lessors shall not declare a default, and that Lessors is required to provide advance notice of a default.
	As previously reported, the Company entered into a Confidential Mutual Release and Settlement Agreement (the “Definitive Settlement Agreement”), effective December 30, 2013, with the Lessors. The Definitive Settlement Agreement provides that it will obtain title to all equipment under the equipment lease upon the payment to the Lessors of approximately $4.8 million over the next twelve months. In addition, under the Definitive Settlement Agreement the Company and the Lessors released each other from any and all claims related to the companion lawsuits, as well as dismissed such lawsuits. In connection with the Definitive Settlement Agreement, during the three months ended December 31, 2013, the Company recognized $3.6 million of interest expense representing the difference between the carrying value of the debt and the present value of the settlement amount.
	Commonwealth of Pennsylvania Financing Authority Loan
	In December 2010, Cross Farm received a $2.25 million loan from the Commonwealth of Pennsylvania for land and the construction of its current manufacturing facility. The loan bears interest at a rate of 5.00% per annum, matures in January 2021 and is secured by a third mortgage on the facility. In connection with the loan agreement, Cross Farm entered into an intercreditor agreement by which the Commonwealth of Pennsylvania agreed that it would not exercise its rights in the event of a default by Cross Farm without the consent of Metro, which holds the first and second mortgages on the facility.

Net_Loss_Per_Share

Net Loss Per Share	6 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	8. Net Loss Per Share
	The Company’s net loss per share is as follows:
		Three Months Ended						Six Months Ended
		December 31,						December 31,
		2013			2012			2013			2012
		(In thousands, except share and per share data)
	Numerator
	Net loss	$	(16,283	)	$	(14,640	)	$	(27,527	)	$	(27,137	)
	Denominator
	Weighted average number of shares used to compute basic net loss per share		97,868,961			77,622,481			95,851,282			77,525,619
	Effect of dilutive options to purchase common stock		—			—			—			—
	Weighted average number of shares used to compute diluted net loss per share		97,868,961			77,622,481			95,851,282			77,525,619
	Basic and diluted net loss per share	$	(0.17	)	$	(0.19	)	$	(0.29	)	$	(0.35	)
	Due to the Company’s net losses, unvested shares of restricted stock (participating securities) totaling 2,612,449 and 5,510,846 were excluded from the calculation of basic and diluted net loss per share during the three months ended December 31, 2013 and 2012, respectively and unvested shares of restricted stock (participating securities) totaling 2,880,150 and 4,967,496 were excluded from the calculation of basic and diluted net loss per share during the six months ended December 31, 2013 and 2012, respectively.
	In addition, stock options (non-participating securities) totaling 5,244,095 and 8,427,743 during the three months ended December 31, 2013 and 2012, respectively, were excluded from the calculation of diluted net loss per share and stock options (non-participating securities) totaling 5,763,630 and 9,240,923 during the six months ended December 31, 2013 and 2012, respectively, were excluded from the calculation of diluted net loss per share, as their effect would have been anti-dilutive. Certain of these stock options were excluded solely due to the Company’s net loss position. Had the Company reported net income during the three months ended December 31, 2013 and 2012, these shares would have had an effect of 207,119 and 279,094 diluted shares, respectively, for purposes of calculating diluted net loss per share. Had the Company reported net income during the six months ended December 31, 2013 and 2012, these shares would have had an effect of 351,346 and 431,092 diluted shares, respectively, for purposes of calculating diluted net loss per share.

Contingencies

Contingencies	6 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Contingencies	'
	9. Contingencies
	From time to time, the Company is involved in various legal proceedings, claims, suits and complaints arising out of the normal course of business. Based on the facts currently available to the Company, management believes that these claims, suits and complaints are adequately provided for, covered by insurance, without merit or not probable that an unfavorable outcome will result.
	As previously disclosed, on September 7, 2012, the Company received a letter from counsel for Talbot (Todd) Smith, a former employee, alleging that Mr. Smith was wrongly terminated. Mr. Smith, who was terminated “for cause” by the Company, filed a complaint with the Occupational Safety & Health Administration (“OSHA”) in November 2012. The Company and various third parties have investigated the allegations made by Mr. Smith and have determined that the allegations are without merit. The Company believes the allegations made by Mr. Smith against the Company are in retaliation for his “for cause” termination and has been defending itself vigorously in the OSHA matter. Because OSHA did not make a final determination on Mr. Smith’s complaint within 180 days, Mr. Smith filed a complaint with the U.S. District Court for the Eastern District of Pennsylvania (“USDC”) on August 30, 2013. The USDC complaint makes the same allegations made by Mr. Smith in the OSHA complaint and does not make any additional material allegations. Given that the allegations made by Mr. Smith in the USDC complaint are nearly identical to those made in his OSHA complaint, the Company and various third parties have investigated the allegations previously and have determined that the allegations are without merit, and the Company will defend itself vigorously in court. The case is currently in discovery. Given that Mr. Smith filed the complaint with the USDC, OSHA dismissed the OSHA matter without a final determination.
	As previously disclosed, subsequent to the filing of the OSHA complaint by Mr. Smith on February 12, 2013, the Company received a subpoena from the staff of the U.S. Securities and Exchange Commission (the “Staff”) requesting the Company to provide certain information to the Staff, which is generally consistent with the meritless allegations made by Mr. Smith in his OSHA complaint. In the USDC complaint, Mr. Smith states that he provided the Staff with information about his allegations in July and August 2012. The Company responded to that subpoena and received a second subpoena from the Staff, requesting additional information consistent with the first subpoena. The Company is cooperating fully with the Staff and has provided the requested information.
	As previously disclosed, on November 1, 2013, the Company and certain of its officers were named as defendants in a purported class action lawsuit filed in the United States District Court for the Middle District of Pennsylvania alleging violations of the federal securities laws. The lawsuit was brought on behalf of a purported stockholder of the Company and all other similarly situated stockholders who purchased the Company’s securities between July 13, 2011 and September 9, 2013 (the “Class Period”). The complaint was mainly based on the meritless allegations made by Mr. Smith in his complaint and generally alleged that the defendants made false and misleading statements regarding the Company’s business, operations and prospects, which allegedly caused the plaintiff and other members of the purported class to purchase the Company’s securities at inflated prices during the Class Period. The lawsuit sought unspecified damages. There were no additional filings by parties seeking to be designated as the lead plaintiff by the required December 31, 2013 deadline, and the plaintiff filed a Notice of Voluntary Dismissal without Prejudice on January 7, 2014, so this matter has concluded.
	On January 8, 2014, the Company was served with a derivative complaint filed in the Delaware Chancery Court by Cambridge Retirement System, a purported shareholder of the Company, against the Company’s Board of Directors to recover allegedly “excessive and wasteful” compensation paid to the non-executive directors since 2010. The Company believes that these allegations are baseless and without merit given that the Company has received favorable say-on-pay votes at the last three annual shareholders meetings and the shareholders previously have voted in favor of the equity grants to the directors, which is required under ASX listing rules, as recently as November 2013. The Company and the directors will defend themselves vigorously in this matter and expect to file a motion to dismiss in response to the complaint by Cambridge in lieu of an answer. The Company does not believe there will be any material impact to the Company or its business.
	The Company does not believe there will be any material impact to the Company or its business as a result of these matters.

Business_Alliances

Business Alliances	6 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Business Alliances	'
	10. Business Alliances
	Sanofi
	The Company signed an exclusivity agreement and an industrialization agreement with Sanofi, a multinational pharmaceutical company, between June 2008 and July 2009. Under the terms of these agreements, Sanofi had agreed to pay the Company an aggregate of approximately $36.4 million in exclusivity fees and industrialization milestone payments for the exclusive right to negotiate the purchase of the Unifill ready-to-fill (prefilled) syringe (Unifill syringe or product) which was developed pursuant to the agreements. Sanofi had paid the Company a €10.0 million ($13.0 million) up front non-refundable one-time fee which the Company was recognizing as revenue over the expected term of the agreement.
	On September 3, 2013, the Company and Sanofi entered into a supply agreement and terminated both the exclusivity agreement and the industrialization agreement. As a result, the Company has recognized the remaining unamortized revenue of $2.3 million during the six months ended December 31, 2013. Under the terms of the supply agreement, the Company has granted Sanofi the exclusive use of the Unifill Finesse with anti-thrombotic drugs during the contract period. Following a four year ramp-up period after market entry, exclusivity will be maintained, subject to Sanofi purchasing a minimum of 150 million units of the Unifill Finesse or other Unifill syringes per year. The Company can supply its Unifill syringes, including the Unifill Finesse, to additional customers in all other therapeutic classes outside of anti-thrombotics. In addition to future revenue from the sale of Unifill Finesse syringes, the Company may receive up to $15 million from Sanofi in milestone-based payments with $5.0 million of these payments received in October 2013. This supply contract replaces and supersedes all other agreements previously signed between both parties regarding the Unifill syringe platform.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Unilife Corporation and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The estimates are principally in the areas of revenue recognition and share-based compensation expense. Management bases its estimates on historical experience and various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.
Inventories	'
	Inventories
	Inventories consist primarily of syringe components and include direct materials, direct labor and manufacturing overhead. Inventories are stated at the lower of cost or market, with cost determined using the first in, first out method. The Company routinely reviews its inventory for obsolete, slow moving or otherwise impaired inventory and records estimated impairments in the periods in which they occur.
Share-Based Compensation	'
	Share-Based Compensation
	The Company grants equity awards to its employees, directors and consultants. Certain employee and director awards vest over stated vesting periods and others also require achievement of specific performance or market conditions. The Company expenses the grant-date fair value of awards to employees and directors over their respective vesting periods. To the extent that employee and director awards vest only upon the achievement of a specific performance condition, expense is recognized over the period from the date management determines that the performance condition is probable of achievement through the date they are expected to be met. Awards granted to consultants are sometimes granted for past services, in which case their fair value is expensed on their grant date, while other awards require future service, or the achievement of performance or market conditions. Timing of expense recognition for consultant awards is similar to that of employee and director awards; however, aggregate expense is re-measured each quarter-end based on the then fair value of the award through the vesting date of the award. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model, with the exception of market-based grants, which are valued based on the Monte Carlo option pricing model. Option pricing methods require the input of highly subjective assumptions, including the expected stock price volatility.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue from industrialization and development fees, licensing fees and product sales.
	The Company recognizes up front, non-refundable fees ratably over the expected life of the related agreement. Revenue from industrialization and development fees is recognized upon achievement of the “at risk” milestone events, which represent the culmination of the earnings process related to such events. Milestones can include specific phases of projects such as product design, prototype availability, user tests, manufacturing proof of principle and the various steps to complete the industrialization of the product. Revenue is recognized when each substantive milestone has been achieved and the Company has no future performance obligations related to the milestone.
	The Company recognizes revenue from sales of products at the time of shipment when title passes to the customer.
Reclassifications	'
	Reclassifications
	Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” (“ASU 2013-02”). The new guidance requires an entity to disclose in a single location the effects of reclassifications out of accumulated other comprehensive income (“AOCI”). For items reclassified out of AOCI and into net income in their entirety, entities must disclose the effect of the reclassification on each affected net income item. For AOCI reclassification items that are not reclassified in their entirety into net income, entities must provide a cross reference to other required U.S. GAAP disclosures. The standard does not change the items which must be reported in other comprehensive income. ASU 2013-02 is effective for annual and interim periods for fiscal years beginning after December 15, 2012. Since this guidance impacts presentation only, it has had no effect on the Company’s financial condition.
	In July 2013, the FASB issued ASC 2013-11, “Income Taxes — Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”) which is part of Accounting Standards Codification (“ASC”) 740: Income Taxes. The new guidance requires an entity to present an unrecognized tax benefit and an NOL carryforward, a similar tax loss, or a tax credit carryforward on a net basis as part of a deferred tax asset, unless the unrecognized tax benefit is not available to reduce the deferred tax asset component or would not be utilized for that purpose, then a liability would be recognized. ASU 2013-11 is effective for annual and interim periods for fiscal years beginning after December 15, 2013. The Company is currently evaluating the impact of the July 1, 2014 adoption of this guidance on its financial statements.

Equity_Transactions_and_ShareB1

Equity Transactions and Share-Based Compensation (Tables)	6 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Stock Options Activity by Employees and Directors	'
	The following is a summary of activity related to stock options held by employees and directors during the six months ended December 31, 2013:
		Number of			Weighted			Weighted		Aggregate Intrinsic
		Options			Average			Average		Value
					Exercise Price			Remaining
								Contractual
								Life (in years)
										(in thousands)
	Outstanding as of July 1, 2013		5,121,807		$	4.05
	Cancelled		(74,396	)		5.55
	Exercised		(1,250,000	)		1.76
	Outstanding as of December 31, 2013		3,797,411		$	4.77			5.5	$	2,068
	Exercisable as of December 31, 2013		1,666,024		$	4.8			5.7	$	755
Schedule of Stock Options Activity by Other than Employees and Directors	'
	The following is a summary of activity related to stock options and warrants held by persons other than employees and directors during the six months ended December 31, 2013:
		Number of			Weighted			Weighted		Aggregate Intrinsic
		Options			Average			Average		Value
					Exercise Price			Remaining
								Contractual
								Life (in years)
										(in thousands)
	Outstanding as of July 1, 2013		4,258,937		$	6.89
	Granted		300,000			3.11
	Exercised		(155,000	)		2.56
	Expired		(2,268,934	)		8.65
	Outstanding as of December 31, 2013		2,135,003		$	4.8			1.9	$	888
	Exercisable as of December 31, 2013		1,135,003		$	4.09			2.6	$	888
Fair Value of Options Granted	'
	The Company used the following weighted average assumptions in calculating the fair value of options granted during the six months ended December 31, 2013 and 2012:
		Six Months Ended
		December 31,
		2013			2012
	Number of stock options granted		300,000			300,000
	Expected dividend yield		0	%		0	%
	Risk-free interest rate		1.54	%		0.91	%
	Expected volatility		55	%		55	%
	Expected life (in years)		5			6
Summary of Activity Related to Restricted Stock Awards	'
	The following is a summary of activity related to restricted stock awards during the six months ended December 31, 2013:
		Number of Restricted			Weighted Average
		Stock Awards			Grant Date Fair Value
	Unvested as of July 1, 2013		3,254,403		$	3.31
	Granted		75,000			3.54
	Vested		(929,150	)		3.35
	Cancelled		(4,500	)		3.46
	Unvested as of December 31, 2013		2,395,753		$	3.3

Property_Plant_and_Equipment_a1

Property, Plant and Equipment and Construction-in-Progress (Tables)	6 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Components of Property, Plant and Equipment and Construction-in-Progress	'
	Property, plant and equipment consist of the following:
		December 31,			June 30,
		2013			2013
		(in thousands)
	Building	$	32,188		$	32,188
	Machinery and equipment		18,632			21,682
	Computer software		2,653			2,653
	Furniture and fixtures		583			374
	Construction in progress		481			91
	Land		2,036			2,036
	Leasehold improvements		166			88
			56,739			59,112
	Less: accumulated depreciation and amortization		(11,427	)		(13,006	)
	Property, plant and equipment, net	$	45,312		$	46,106

Goodwill_Tables

Goodwill (Tables)	6 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Changes in Carrying Amount of Goodwill	'
	The changes in the carrying amount of goodwill during the six months ended December 31, 2013 are as follows:
		(in thousands)
	Balance as of July 1, 2013	$	11,498
	Foreign currency translation		(332	)
	Balance as of December 31, 2013	$	11,166

LongTerm_Debt_Tables

Long-Term Debt (Tables)	6 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Components of Long-Term Debt	'
	Long-term debt consists of the following:
		December 31, 2013		June 30, 2013
		(In thousands)
	6.00% Mortgage loan, due December 2031	$	13,474	$	13,677
	6.00% Mortgage loan, due October 2020		3,170		3,322
	14.00% Secured lending facility, due December 2014		4,364		2,586
	4.75% Bank term loans, due January 2021 through August 2021		1,611		1,701
	5.00% Commonwealth of Pennsylvania financing authority loan, due January 2021		2,108		2,133
	Other		429		452
			25,156		23,871
	Less: current portion of long-term debt		5,596		3,826
	Total long-term debt	$	19,560	$	20,045

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	6 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	The Company’s net loss per share is as follows:
		Three Months Ended						Six Months Ended
		December 31,						December 31,
		2013			2012			2013			2012
		(In thousands, except share and per share data)
	Numerator
	Net loss	$	(16,283	)	$	(14,640	)	$	(27,527	)	$	(27,137	)
	Denominator
	Weighted average number of shares used to compute basic net loss per share		97,868,961			77,622,481			95,851,282			77,525,619
	Effect of dilutive options to purchase common stock		—			—			—			—
	Weighted average number of shares used to compute diluted net loss per share		97,868,961			77,622,481			95,851,282			77,525,619
	Basic and diluted net loss per share	$	(0.17	)	$	(0.19	)	$	(0.29	)	$	(0.35	)

Liquidity_Additional_Informati

Liquidity - Additional Information (Detail) (USD $)	6 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Oct. 31, 2012
		Subsequent Event [Member]	Maximum [Member]
Liquidity And Capital Resources [Line Items]	'	'	'
Aggregate offering price	'	'	$45,000,000
Number of shares of common stock issued	3,512,153	1,500,000	'
Remaining amount available under the Sales Agreement	19,200,000	'	'
Value of new stock issued	$10,668,000	$6,200,000	'

Equity_Transactions_and_ShareB2

Equity Transactions and Share-Based Compensation - Additional Information (Detail)	0 Months Ended	3 Months Ended		6 Months Ended		7 Months Ended	6 Months Ended				0 Months Ended
In Millions, except Share data, unless otherwise specified	Nov. 30, 2009	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Jan. 27, 2010	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Jan. 31, 2010
		USD ($)	USD ($)	USD ($)	USD ($)		Minimum [Member]	Maximum [Member]	Employee Stock Option [Member]	Employee Stock Option [Member]	Stock Incentive Plan [Member]
							AUD	AUD	Minimum [Member]	Maximum [Member]	AUD
Equity Transactions And Share Based Compensation [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Share-based compensation expense	'	$2.60	$2.90	$5.30	$4.50	'	'	'	'	'	'
Issuance of common stock to directors	'	227,500	'	'	'	'	'	'	'	'	'
Grant date fair value	'	$3.95	'	$0.97	'	'	'	'	'	'	'
Fair value of the options being expensed, service period	'	'	'	'	'	'	'7 months 10 days	'9 months 11 days	'1 year	'3 years	'
Maximum shares not considered for sale and transfer	6,000,000	'	'	'	'	'	'	'	'	'	'
Share reserve adjustment percentage	17.50%	'	'	'	'	'	'	'	'	'	'
Granted options to purchase common stock	'	'	'	'	'	'	'	'	'	'	1,000,000
Price of exercisable options per share	'	'	'	'	'	'	'	'	'	'	6.33
Stock price requirement for vesting of options	'	'	'	'	'	'	1.75	3.22	'	'	'
Total intrinsic value	'	$0	$0.10	$1.80	$0.10	'	'	'	'	'	'
Expected dividend yield	'	'	'	'	'	0.00%	'	'	'	'	'

Equity_Transactions_and_ShareB3

Equity Transactions and Share-Based Compensation - Schedule of Stock Options Activity by Employees and Directors (Detail) (Employees and Board Directors [Member], USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013
Employees and Board Directors [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Options, Outstanding, Beginning	5,121,807
Number of Options, Cancelled	-74,396
Number of Options, Exercised	-1,250,000
Number of Options, Outstanding, Ending	3,797,411
Number of Options, Exercisable, Ending	1,666,024
Weighted Average Exercise Price, Outstanding, Beginning	$4.05
Weighted Average Exercise Price, Cancelled	$5.55
Weighted Average Exercise Price, Exercised	$1.76
Weighted Average Exercise Price, Outstanding, Ending	$4.77
Weighted Average Exercise Price, Exercisable, Ending	$4.80
Weighted Average Remaining Contractual Life (in years), Outstanding Balance	'5 years 6 months
Weighted Average Remaining Contractual Life (in years), Exercisable Balance	'5 years 8 months 12 days
Aggregate Intrinsic Value, Outstanding Balance	$2,068
Aggregate Intrinsic Value, Exercisable Balance	$755

Equity_Transactions_and_ShareB4

Equity Transactions and Share-Based Compensation - Schedule of Stock Options Activity by Other than Employees and Directors (Detail) (Other Than Employees and Directors Warrants [Member], USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013
Other Than Employees and Directors Warrants [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Options, Outstanding, Beginning	4,258,937
Number of Options, Granted	300,000
Number of Options, Exercised	-155,000
Number of Options, Expired	-2,268,934
Number of Options, Outstanding, Ending	2,135,003
Number of Options, Exercisable, Ending	1,135,003
Weighted Average Exercise Price, Outstanding, Beginning	$6.89
Weighted Average Exercise Price, Granted	$3.11
Weighted Average Exercise Price, Exercised	$2.56
Weighted Average Exercise Price, Expired	$8.65
Weighted Average Exercise Price, Outstanding, Ending	$4.80
Weighted Average Exercise Price, Exercisable, Ending	$4.09
Weighted Average Remaining Contractual Life (in years), Outstanding Balance	'1 year 10 months 24 days
Weighted Average Remaining Contractual Life (in years), Exercisable Balance	'2 years 7 months 6 days
Aggregate Intrinsic Value, Outstanding Balance	$888
Aggregate Intrinsic Value, Exercisable Balance	$888

Equity_Transactions_and_ShareB5

Equity Transactions and Share-Based Compensation - Fair Value of Options Granted (Detail)	7 Months Ended	6 Months Ended
	Jan. 27, 2010	Dec. 31, 2013	Dec. 31, 2012
		Stock Options [Member]	Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of stock options granted	'	300,000	300,000
Expected dividend yield	0.00%	0.00%	0.00%
Risk-free interest rate	'	1.54%	0.91%
Expected volatility	'	55.00%	55.00%
Expected life (in years)	'	'5 years	'6 years

Equity_Transactions_and_ShareB6

Equity Transactions and Share-Based Compensation - Summary of Activity Related to Restricted Stock Awards (Detail) (Restricted Stock [Member], USD $)	6 Months Ended
	Dec. 31, 2013
Restricted Stock [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Restricted Stock Awards, Unvested, Beginning balance	3,254,403
Number of Restricted Stock Awards, Granted	75,000
Number of Restricted Stock Awards, Vested	-929,150
Number of Restricted Stock Awards, Cancelled	-4,500
Number of Restricted Stock Awards, Unvested, Ending balance	2,395,753
Weighted Average Grant Date Fair Value, Unvested, Beginning Balance	$3.31
Weighted Average Grant Date Fair Value, Granted	$3.54
Weighted Average Grant Date Fair Value, Vested	$3.35
Weighted Average Grant Date Fair Value, Cancelled	$3.46
Weighted Average Grant Date Fair Value, Unvested, Ending Balance	$3.30

Property_Plant_and_Equipment_a2

Property, Plant and Equipment and Construction-in-Progress - Components of Property, Plant and Equipment and Construction-in-Progress (Detail) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Property Plant And Equipment [Abstract]	'	'
Building	$32,188	$32,188
Machinery and equipment	18,632	21,682
Computer software	2,653	2,653
Furniture and fixtures	583	374
Construction in progress	481	91
Land	2,036	2,036
Leasehold improvements	166	88
Property, plant and equipment, gross	56,739	59,112
Less: accumulated depreciation and amortization	-11,427	-13,006
Property, plant and equipment, net	$45,312	$46,106

Goodwill_Changes_in_Carrying_A

Goodwill - Changes in Carrying Amount of Goodwill (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Beginning Balance	$11,498
Foreign currency translation	-332
Ending Balance	$11,166

LongTerm_Debt_Components_of_Lo

Long-Term Debt - Components of Long-Term Debt (Detail) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Long-term debt	$25,156	$23,871
Less: current portion of long-term debt	5,596	3,826
Total long-term debt	19,560	20,045
6.00% Mortgage Loan, Due December 2031 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	13,474	13,677
6.00% Mortgage Loan, Due October 2020 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	3,170	3,322
14.00% Secured Lending Facility, Due December 2014 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	4,364	2,586
4.75% Bank Term Loans, Due January 2021 Through August 2021 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	1,611	1,701
5.00% Commonwealth of Pennsylvania Financing Authority Loan, Due January 2021 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	2,108	2,133
Other [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	$429	$452

LongTerm_Debt_Components_of_Lo1

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	6 Months Ended
	Dec. 31, 2013
6.00% Mortgage Loan, Due December 2031 [Member]	'
Debt Instrument [Line Items]	'
Long-term debt, percentage	6.00%
Long-term debt, due date	31-Dec-31
6.00% Mortgage Loan, Due October 2020 [Member]	'
Debt Instrument [Line Items]	'
Long-term debt, percentage	6.00%
Long-term debt, due date	31-Oct-20
14.00% Secured Lending Facility, Due December 2014 [Member]	'
Debt Instrument [Line Items]	'
Long-term debt, percentage	14.00%
Long-term debt, due date	31-Dec-14
4.75% Bank Term Loans, Due January 2021 Through August 2021 [Member]	'
Debt Instrument [Line Items]	'
Long-term debt, percentage	4.75%
Long-term debt, due date	'January 2021 through August 2021
5.00% Commonwealth of Pennsylvania Financing Authority Loan, Due January 2021 [Member]	'
Debt Instrument [Line Items]	'
Long-term debt, percentage	5.00%
Long-term debt, due date	31-Jan-21

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

3 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2013

Aug. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2010

Dec. 31, 2013

Oct. 31, 2010

Oct. 31, 2010

Oct. 31, 2010

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2013

Secured Lending Facility [Member]

Secured Lending Facility [Member]

Definitive Settlement Agreement [Member]

Commonwealth of Pennsylvania Financing Authority Loan [Member]

Commonwealth of Pennsylvania Financing Authority Loan [Member]

Mortgage Loans [Member]

Mortgage Loan 1 [Member]

Mortgage Loan 2 [Member]

Mortgage Term Note [Member]

Mortgage Loans [Member]

Mortgage Loans [Member]

Note

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of mortgage loans

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

Mortgage loans, amount

$25,156,000

'

'

$25,156,000

'

$23,871,000

'

'

'

'

'

'

$14,250,000

$3,750,000

'

'

'

Additional interest rate on Prime Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.50%

'

'

Debt instrument floor interest rate during period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.50%

'

'

Interest rate per annum

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

6.00%

'

Weighted average interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

6.00%

Debt Service Reserve Account

2,400,000

'

'

2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum balance in Debt Service Reserve Account

1,600,000

'

'

1,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of loans guaranteed by U.S. Department of Agriculture

10,000,000

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Master Lease Agreement with Varilease Finance, Inc. for secured financing

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

Effective interest rate

'

'

'

'

'

'

14.00%

'

'

'

'

'

'

'

'

'

'

Frequency of payment as per agreement

'

'

'

'

'

'

'

'27 monthly installments based upon the amount drawn

'

'

'

'

'

'

'

'

'

Lease buyout rate

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease period

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional lease period

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease payment

4,800,000

'

'

4,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense

4,351,000

'

645,000

4,831,000

1,261,000

'

'

'

3,600,000

'

'

'

'

'

'

'

'

Loan amount for financing for land and construction of current manufacturing facility

'

'

'

'

'

'

'

'

'

$2,250,000

'

'

'

'

'

'

'

Maturity date of loan

'

'

'

'

'

'

'

'

'

'

31-Jan-21

'

'

'

'

'

'

Net_Loss_Per_Share_Net_Loss_Pe

Net Loss Per Share - Net Loss Per Share (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Numerator	'	'	'	'
Net loss	($16,283)	($14,640)	($27,527)	($27,137)
Denominator	'	'	'	'
Weighted average number of shares used to compute basic net loss per share	97,868,961	77,622,481	95,851,282	77,525,619
Effect of dilutive options to purchase common stock	'	'	'	'
Weighted average number of shares used to compute diluted net loss per share	97,868,961	77,622,481	95,851,282	77,525,619
Basic and diluted net loss per share	($0.17)	($0.19)	($0.29)	($0.35)

Net_Loss_per_Share_Additional_

Net Loss per Share - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Net Income Per Share [Line Items]	'	'	'	'
Incremental shares in case of profit for calculating diluted earnings per share	'	'	'	'
Restricted Stock [Member]	'	'	'	'
Net Income Per Share [Line Items]	'	'	'	'
Share excluded from calculation of basic and diluted net loss per share	2,612,449	5,510,846	2,880,150	4,967,496
Employee Stock Option [Member]	'	'	'	'
Net Income Per Share [Line Items]	'	'	'	'
Share excluded from calculation of basic and diluted net loss per share	5,244,095	8,427,743	5,763,630	9,240,923
Incremental shares in case of profit for calculating diluted earnings per share	207,119	279,094	351,346	431,092

Business_Alliances_Additional_

Business Alliances - Additional Information (Detail) (Sanofi [Member])	6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013
	USD ($)	EUR (€)
	Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Exclusivity fees and industrialization milestone payments	$36.40	'
Up front fee	13	10
Unamortized revenue recognized	2.3	'
Ramp-up period after market entry	'4 years	'4 years
Minimum purchase per year	150,000,000	150,000,000
Milestone-based payments	15	'
Milestone-based payments, received	$5	'